Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA
|
|
- Francis Doyle
- 6 years ago
- Views:
Transcription
1 Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA CHRONIC OPIOID USE FOR NON-MALIGNANT PAIN 1. PURPOSE: To establish guidance for safe and effective use of opioids in the management of chronic non-malignant pain. 1. BACKGROUND: A n increase in opioid prescribing over the past ten years has resulted in significant increases in overdose deaths, treatment admissions, ED visits for misuse or abuse, dependency, nonmedical users, and diversion. The risk of opioid overdose has increased among VA patients, the risk rising with increased daily dose. 2. POLICY: Safe and effective management of pain in the care of Veterans is a priority for the Veterans Health Administration. In particular VHA seeks to reduce harm from unsafe medications and/or excessive doses, or excessive duration of treatment, while optimizing pain management strategies for all Veterans. Optimal treatment of chronic pain requires a coordinated multi-modality, interdisciplinary approach. Opioids are an important component of pain management but are rarely appropriate as first-line or sole treatment options. Excluded from this policy are patients receiving opioid therapy for treatment of cancer-related pain, and in end-of-life or palliative care situations. 3. DEFINITION: a. Chronic Non-Malignant Pain. In general, it is defined as any continuous pain lasting longer than (3) months. It may or may not have an identifiable organic cause and typically includes exacerbations and remissions. Treatment goals focus on improved quality of life and physical and psychosocial functioning. b. Breakthrough Pain. Transient exacerbation of pain that occurs in patients with otherwise stable baseline persistent pain. c. Chronic Opioid Use. Consistent use of a DEA schedule II or III opioid for greater than or equal to 90 calendar days. 4 GUIDANCE: a. Initial Patient Assessment 1) All opioid prescribers are advised to follow the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain provides practitioner guidance on initial patient assessment and determination of appropriateness of opioid therapy for chronic pain. If determination that 1
2 treatment is indicated, the treatment plan must be included as part of the documentation. 2) To make sure all key elements are included in the initial assessment, it is recommended that a standardized note template be utilized, Initial Assessment of Chronic Opioid Therapy. b. Opioid Agreement 1) A nationally standardized IMED consent for long-term opioid therapy for pain management must be completed on all patients on chronic opioid therapy. This requirement does not apply to patients enrolled in hospice, or patients receiving long-term opioids for cancer pain. All requirements for VHA Directive 1005 must be met. 2) A Clinical Reminder must be established to ensure this consent process is completed in all patients on chronic opioid therapy. This is a one-time clinical reminder. 3) Essential elements of this Directive include: a) Completing the informed consent process b) Providing the patient a copy of the standardized patient information guide titled "Taking Opioids responsibly for Your Safety and the Safety of Others" c) Reviewing and discussing the contents of the information guide with the patient. d) Developing and publishing a local policy and procedures consistent with the requirements of VHA Directive c. Follow-up Assessment a) All opioid prescribers are advised to follow the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain which provides practitioner guidance on follow-up assessment and appropriate assessment intervals. b) Assessments must be done every 1-6 months during the duration of maintenance therapy. c) It is recommended that a Clinical Reminder be established to ensure assessments are completed at a minimum of every 6 months. The Clinical Reminder should link to a standardized Opioid Therapy Assessment Note that contains the essential elements needed to assess patients on chronic opioid therapy. d. Urine Drug Screening (UDS) a) UDS is utilized to mitigate risk of opioid prescribing. b) VISN PLMS will provide comprehensive testing to include testing for semisynthetic and synthetic opioids, and confirmatory testing where needed. c) The frequency of UDS must be annually at a minimum, with more frequent testing based upon risk stratification. d) It is recommended that a Clinical Reminder be established to ensure UDSs are completed at a minimum of every 12 months and when initiating an opioid as therapy. e. Prescription Drug Monitoring Program (PDMP) 2
3 a) Please refer to VISN policy on State Prescription Drug Monitoring Program. b) PDMP's are designed to detect and prevent prescription drug abuse by identifying individuals who seek to obtain prescriptions for addictive medications from multiple providers. c) The PDMP should be reviewed prior to initiating chronic opioid therapy. d) The frequency of PDMP searches should occur at least initially and annually thereafter for patients prescribed chronic opioids. Patients at higher risk for opioid misuse should have more frequent PDMP monitoring. e) It is recommended that a Clinical Reminder be established to ensure PDMP searches are completed at a minimum of every 12 months. The CR will be linked to the standardized note title, State Prescription Drug Monitoring Program. This note includes the necessary components required to meet Privacy regulations when searching PDMP. f. Discontinuation of Chronic Opioids a) If a patient's chronic opioid medication(s) is discontinued, the reason for discontinuance must be documented in CPRS. b) If there is no documented support for continued use, the patient should be tapered off opioids and other treatment options should be explored. If appropriate, consults to Pain Management, Substance Abuse clinics, or other modalities should be considered. c) Patients who abrogate their Opiate Informed Consent should not be prescribed opiates and offered gradual dose reduction when clinically appropriate. d) If there is suspicion or evidence of current abuse of alcohol, opiates, benzodiazepines, or illegal drugs/substances, the provider should discontinue opioids and consult the Substance Abuse Treatment Clinic (SATC) for evaluation and further recommendations. e) If a provider has objective evidence of misuse, opioids are immediately tapered off or discontinued, considering the need for appropriate tapering as medically necessary. Other medically acceptable means of "detoxification" may be used if needed. f) For safety reasons in patients receiving chronic opioid therapy for nonmalignant pain, if UDS detects marijuana, opioid therapy will be tapered and discontinued if the patient elects to continue use of any form of marijuana and opioids concurrently. Marijuana use will be documented in CPRS under non-va medication. g. Opioid Prescribing Procedures a) Except in cases where there is documentation of collaboration between providers for the treatment of the patient's chronic pain (i.e. pain clinic), patients may only be prescribed opioids for their chronic pain by their designated or covering provider; a covering provider must be available at all times. b) Patients on chronic opioid therapy for non-malignant pain should not receive prescriptions in the ED, except as a 3-day emergency supply (if prescription 3
4 records indicate they have exhausted their supply). Exceptions for travelling can be considered on a case-by-case basis. Signage shall be posted in the ED waiting areas to inform patients of the opioid prescribing rules and their responsibilities. c) Prescriptions for opioids are limited to 30-day supplies or less. d) 2 8-day renewal cycles for schedule II opioid prescriptions are strongly encouraged to coordinate refill schedules, reduce out-of-meds requests and walk-in visits. e) Due to safety reasons, concurrent prescribing of opioids and benzodiazepines are strongly discouraged. There must be a strong clinical justification for combined use, where other alternatives can be considered. Facilities are encouraged to use processes such as a prior authorization or order check to educate providers and limit use of this combination. In particular, the combination of methadone and benzodiazepine is considered a critical drug interaction. f) The maximal morphine equivalent dose (MED) that can be prescribed by a Primary Care Provider will be 120 mg unless prescribed by a designated pain expert. Dose escalations above 120 morphine equivalents (whether existing, or new patient) will require second level review or prior authorization. Such concurrence may be at the facility's option, such as requiring consultation with appropriate specialties e.g. Step Two pain referral, Rehabilitation Medicine, Palliative Care, Rheumatology etc. g) Use of short-acting opioids in the treatment of chronic pain is discouraged. Sites should consider quantity limit of 120 short-acting opioids per 30-day supply (exception oncology, palliative care, pain clinic providers). 5. RESPONSIBILITY: a. Chief of staff is responsible for implementation and monitoring of compliance with this Network policy. b. Opioid prescribers are responsible for: 1) Following guidance described in this Network policy. 2) Addressing clinical reminders as recommended in this guidance c. Pharmacy service is responsible for: 1) Providing opioid utilization data for provider review. 2) Communicate to providers opioid prescriptions that appear to contribute to misuse, diversion, abuse, etc. and document concerns. d. ACOS/Education is responsible for providing training opportunities on pain management topics. 6, REFERENCES: a. Chou, R.; et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. Journal of Pain. Vol 10, Issue 2. Pages e22 (February 2009) b. Department of Veterans Affairs; Department of Defense. VA/DoD CLINICAL Practice Guideline for the Management of Opioid Therapy for Chronic Pain. March 2003, Version
5 c. Department of Veterans Affairs. Pain Management. VHA Directive October 28, d. Dunn K M, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ami Intern Med. 2010;152(2): e. Bohnert ASB, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF,Ilgen MA, Blow FC Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 305: f. Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011; 171: g. Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: Preliminary validation ofthe Opioid Risk Tool. Pain Med 6: , 2005 h. VHA Directive 1005, Informed Consent for Long-Term Opioid therapy for Pain, May 6, FOLLOW-UP RESPONSIBILITY: The Office of Network Director, Chief Medical Officer, is responsible for the contents of this Policy. 8. RESCISSION: None 9. RECERTIFICATION DATE: 10. AUTHORIZATION / APPROVING OFFICIAL: VA Desert Pacific Healthcare Network Date Distribution: Network 22 facilities 5
Proposed Revision to Med (i)
Proposed Revision to Med 501.02 (i) I. Purpose This rule has been adopted to enable the Board to best protect public health and safety while providing a framework for licensees to effectively treat and
More informationTennessee. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioid Safety Initiative. Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services
Opioid Safety Initiative Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services 1 2 Opioid Safety Initiative (OSI) Overdose Education and Naloxone Distribution (OEND):
More informationStandard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)
Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care) Preamble This Standard establishes the standards of practice and ethical requirements of all physicians
More informationOklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES
TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationRecommendations in Opioid Prescribing Guidelines for Chronic Pain
Recommendations in Opioid Prescribing Guidelines for Chronic Pain The use of opioids for treating chronic pain has been increasing. 1 In 2010, an estimated 20% of patients presenting to physician offices
More informationLouisiana. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationRhode Island. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationAddressing the Opioid Epidemic in the Veterans Health Administration
Addressing the Opioid Epidemic in the Veterans Health Administration Julie Gochnour, MD Governor s Working Group on Veterans, Service Members, and Their Families May 25, 2017 Overview Epidemiology of the
More informationVirginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationPrescription Monitoring Program (PMP)
06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid
More informationSix Building Blocks Self-Assessment Questionnaire Workshop Version July 2017
July 2017 Background The Six Building Blocks were developed as part of a research project on Team Based Opioid Management in rural clinics. The three year research study is a collaboration between 20 rural
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationCalifornia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016
Opioids: What You Should Know About Opioid Prescribing Denis G. Patterson, DO Nevada State Medical Association October 19, 2016 Contact Information Denis G. Patterson, DO Nevada Advanced Pain Specialists
More informationMedicaid and the Opioid Crisis
Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers
More informationDisclosures 6/5/2017. Dr. Franklin has no disclosures Dr. Ngo has no disclosures
Tu Ngo, PhD, MPH Julie Franklin, MD, MPH International Conference on Opioids Boston, MA June 11, 2017 1 Disclosures Dr. Franklin has no disclosures Dr. Ngo has no disclosures 2 Objectives Identify areas
More informationMQAC Rules for the Management of Chronic Non-Cancer Pain For Allopathic Physicians Effective January 2, 2012
MQAC Rules for the Management of Chronic Non-Cancer Pain For Allopathic Physicians Effective January 2, 2012 WAC 246-919-850 Pain management Intent. These rules govern the use of opioids in the treatment
More informationNew Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers
CENTERS FOR MEDICARE & MEDICAID SERVICES New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers Background CMS understands the magnitude of the nation s opioid epidemic and
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More informationEffective Date: May 19, Revised Date: August 18, Policy Number: MED Policy 313. Pain Management Long Term Opioid Use
Effective Date: May 19, 2008 Revised Date: August 18, 2015 Approved by: Thomas M Tocher, MD, MPH, Chief Clinical Officer Policy Number: MED Policy 313 Title: Pain Management Long Term Opioid Use POLICY
More informationWest Virginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile West Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationThe Challenging Patient with Chronic Opioid Usage MD ACP Meeting
The Challenging Patient with Chronic Opioid Usage. 2018 MD ACP Meeting Darius A. Rastegar, MD March 12, 2018 1 Prescribing Opioids: A question of balance Opioids are an effective treatment for acute pain.
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationVermont. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of
More informationPharmaceutical Misuse and its Challenges: Opioid Use in Ontario. Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012
Pharmaceutical Misuse and its Challenges: Opioid Use in Ontario Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012 Objectives To review the prescription opioid crisis To understand the
More informationSection I. Short-acting opioid Prior Authorization Criteria
Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization
More informationSubject: Pain Management (Page 1 of 7)
Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all
More informationPROVIDER BULLETIN. Published by Wyoming Workers Compensation Medical Case Management Unit October 21, 2015
Matthew H. Mead Governor State of Wyoming Department of Workforce Services DIVISION OF WORKERS COMPENSATION 1510 East Pershing Boulevard, South Wing Cheyenne, Wyoming 82002 http://www.wyomingworkforce.org
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationMedication Agreements Promoting awareness, dialogue and level-set expectations
Medication Agreements Promoting awareness, dialogue and level-set expectations A young man had his leg amputated following a work-related injury. His pain doctor, by all accounts, was trying to responsibly
More informationMedicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists Background Opioid medications are effective at treating certain types of pain,
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION. Chronic Pain and Opiate Management Initiatives
PACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION Chronic Pain and Opiate Management Initiatives Objectives To enhance understanding of current concepts, guidelines and risks of
More informationThe Wisconsin Prescription Drug Monitoring Program
The Wisconsin Prescription Drug Monitoring Program DHS 2018 WI Opioid Forum April 12, 2018 Learning Objectives 1. How the WI epdmp supports healthcare professionals in making informed prescribing, dispensing
More informationWHAT YOU NEED TO KNOW TO ABOUT AB 474
WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov
More informationImplementing Pain and Opioid Management Guidelines in Primary Care Practice
Implementing Pain and Opioid Management Guidelines in Primary Care Practice Objectives 1. What is the issue? 2. Why use a dedicated dissemination & implementation process? a. Historical perspective Cooperative
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationClinical and Contextual Evidence Reviews
Clinical and Contextual Evidence Reviews Roger Chou, MD Professor of Medicine Oregon Health & Science University Director, Pacific Northwest Evidence-based Practice Center Purpose Summarize methods for
More informationRULE-MAKING ORDER PERMANENT RULE ONLY. CR-103P (December 2017) (Implements RCW )
CODE REVISER USE ONLY RULE-MAKING ORDER PERMANENT RULE ONLY CR-103P (December 2017) (Implements RCW 34.05.360) Agency: Department of Health- Dental Quality Assurance Commission Effective date of rule:
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationScope of the Opiate Problem 6/5/18. Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond. Overview.
Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond David Anisman, MD Medical Director, Farmington Health Center (Primary Care) Associate Medical Director, Community
More informationApril 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director
More informationThe Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.
The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp
More informationPrescribing drugs of dependence in general practice, Part C
HO O Prescribing drugs of dependence in general practice, Part C Key recommendations and practice points for management of pain with opioid therapy H H HO N CH3 Acute pain Acute pain is an unpleasant sensory
More informationUtah. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Utah Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view
More informationAddressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain
Addressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain Ajay D. Wasan, MD, MSc Professor of Anesthesiology and Psychiatry Vice Chair for Pain Medicine, Department of Anesthesiology University
More information2. Is this request for a preferred medication? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationNurse Practitioner Practice Guideline Treatment Agreements
Nurse Practitioner Practice Guideline Treatment Agreements In November 2012, the New Classes of Practitioners Regulations (NCPR) under Canada s Controlled Drug and Substances Act (CDSA) came into force,
More informationOur Opioid Epidemic. The Opioid Mortality Crisis Continues 3/2/2017 STEPHEN R. BELL, DO
Our Opioid Epidemic STEPHEN R. BELL, DO GOVERNOR S TASK FORCE ON PRESCRIPTION DRUG AND OPIOID ABUSE MICHIGAN STATE COMMISSION ON OPIOID AND PRESCRIPTION DRUG ABUSE CHAIR, MOA PRESIDENTIAL TASK FORCE ON
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationChronic Opioid Therapy Safe Prescribing in Primary Care. Part 3
Chronic Opioid Therapy Safe Prescribing in Primary Care Part 3 Michael Mangione, MD Chief of Anesthesia and Director of Pain Service VA Pittsburgh Health Care System Nancy Wiedemer,CRNP VISN 4 Pain Management
More informationOpioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018
Opioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018 Disclosures None Educational Objectives Understand CA state medical board guidelines for prescribing opioids for chronic pain Understand the
More information3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationNew Guidelines for Opioid Prescribing
New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research
More informationChronic Pain: Decreasing Dependence on Opioids
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 Chronic Pain: Decreasing Dependence on Opioids Derek Luzim Follow this and additional
More informationManagement of Pain - A Comparison of Current Guidelines
Management of Pain - A Comparison of Current Guidelines The Centers for Disease Control and Prevention (CDC) released a guideline in 2016 regarding the prescribing of opioids for chronic non-cancer pain
More informationTHE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING
THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING Ernest J Dole, PharmD, PhC, FASHP, BCPS Clinical Pharmacist University of New Mexico Hospitals And Clinical Associate Professor University
More informationWisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline
Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline: To help providers make informed decisions about acute and chronic pain treatment -pain lasting longer than three months
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Alaska Requires adoption of regulations that provide that a practitioner query the PDMP prior to dispensing, prescribing, or administering a Sch. II or III controlled substance; query is not required for
More informationChronic Disease Management for Pain: It CAN be done in primary care!
Chronic Disease Management for Pain: It CAN be done in primary care! Sondra Adkinson, PharmD, DAAPM, CPE Thomas B. Gregory, Pharm.D., BCPS, DASPE, CPE Chris Herndon, PharmD, BCPS, CPE Disclosures Adkinson:
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationMinnesota. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationAetna s Initiative on the Opioid Epidemic
Aetna s Initiative on the Opioid Epidemic Christopher James D.O., M.P.H. Medical Director, BH- Mid-Atlantic Territory (JamesC1@aetna.com) July 23, 2017 HHS Data on Epidemic Every Day in the U.S. More than
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Effective Date: 04.18 Last Review Date: 04.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationReadopt with amendment Med 502, effective (Document #11090), to read as follows:
Adopted Rules 11-2-16 1 Readopt with amendment Med 502, effective 5-3-16 (Document #11090), to read as follows: PART Med 502 OPIOID PRESCRIBING Med 502.01 Applicability. This part shall apply to the prescribing
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationVanila M Singh, MD MACM Chief Medical Officer Office of the Assistant Secretary for Health U.S. Department of Health and Human Services
Vanila M Singh, MD MACM Chief Medical Officer Office of the Assistant Secretary for Health U.S. Department of Health and Human Services 1 Summit Objectives Engage subject matter experts and key federal,
More informationUSE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT
BACKGROUND: USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT Approximately 10% of patients who are prescribed opioids and seek care from multiple doctors, are prescribed
More informationASPMN Conference Baltimore, Maryland
ASPMN Conference Baltimore, Maryland Prescribing Controlled Substances Managing Risk and Optimizing Outcomes September 13, 2012 Tracey Fremd, NP Tracey Fremd Consulting, Inc. Most Common Uses for Controlled
More informationRevised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017
Revised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017 A. Application of Guidelines Guidelines on Proper Prescription
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 218 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationAlberta WCB Policies & Information
1. What are the objectives of WCB regarding the authorization of prescribed opioid analgesics As part of an overall approach to effective, appropriate claims management, including the provision of and
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationTHE RATE OF OVERDOSE MORTALity
ORIGINAL CONTRIBUTION Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths Amy S. B. Bohnert, PhD Marcia Valenstein, MD Matthew J. Bair, MD Dara Ganoczy, MPH John F. McCarthy,
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationTREATING CHRONIC PAIN AND SUBSTANCE USE DISORDERS: THE ROLE OF OPIOIDS AND CANNABIS
TREATING CHRONIC PAIN AND SUBSTANCE USE DISORDERS: THE ROLE OF OPIOIDS AND CANNABIS Mark Ilgen, PhD VA Center for Clinical Management Research Department of Psychiatry, University of Michigan Acknowledgements
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Analgesics, Narcotic Long Acting and Analgesics, Narcotic Short
More informationDear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good
PAIN MEDICINE Volume 5 Number 3 2004,* Edward Covington, MD, and Patricia M. Good *Georgetown University, Washington, District of Columbia; Cleveland Clinic Foundation, Cleveland, Ohio; Office of Diversion
More informationUS H.R.6 of the 115 th Congress of the United States Session
US H.R.6 of the 115 th Congress of the United States 2017-2018 Session This Act may be cited as the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
More informationPatient Agreement for the use of Opioid Medications
today s date Patient Name date of birth Patient Agreement for the use of Opioid Medications The purpose of this agreement is to give you information about the medications that may be part of your treatment
More informationTeaming Up for Safer Pain Management: Strategies for Effective Collaboration
Teaming Up for Safer Pain Management: Strategies for Effective Collaboration Noah Nesin, MD, FAAFP, Vice President of Medical Affairs, Penobscot Community Health Care Felicity Homsted, PharmD, DPLA, Chief
More informationPractical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR
Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful
More informationMichigan Opioid Legislation Hospital Compliance Checklist
MHA KEYSTONE CENTER MICHIGAN OPIOID LEGISLATION HOSPITAL COMPLIANCE CHECKLIST The Michigan Opioid Legislation was created by the Michigan Health & Hospital Association to help guide its member hospitals
More informationPrescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD
Prescribing Opioids in the Opioid Epidemic Scott Woffinden, PA-C Jason Chapman, JD What's the Problem? http://www.zdoggmd.com/blank-script-taylor-swift-parody/ What's the Problem? CDC 115 Americans die
More informationUse of Opioids for Chronic Non Malignant Pain (CNMP)
I. PURPOSE Use of Opioids for Chronic Non Malignant Pain (CNMP) We the Safe Opioid Prescribing and Review Committee (SOPARC) are inspired to support a shift in opioid prescribing that improves clinical
More informationOpioid Task Force Kick-Off Meeting. February 29, 2016
Opioid Task Force Kick-Off Meeting February 29, 2016 Scope of the Opioid Problem and Data Review Olivia Kasirye, MD, MS County Public Health Officer OVERVIEW The Opioid Epidemic Opioid Task Force Development
More information